Low‐dose colchicine vs NSAIDs
Serious adverse events · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
8 questions · 8 findings · 4 reviews · Musculoskeletal
No studies found 1 · 12.5%GRADE not reported 2 · 25%Very low 3 · 37.5%Low 1 · 12.5%Moderate 1 · 12.5%High 0 · 0%
Low‐dose colchicine vs placebo
Serious adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 133 participantsGRADE not reported
Anti‐TNF discontinuation vs anti‐TNF continuation
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.29 [0.82, 2.03]8 studies · 2095 participantsVery low
Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.24 [0.42, 3.7]2 studies · 317 participantsVery low
Anti‐TNF dose reduction vs anti‐TNF continuation
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.09 [0.65, 1.82]5 studies · 1084 participantsLow
Intermittent/cyclic etidronate 400 mg/day vs placebo
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyRR 0.9 [0.52, 1.54]Studies not reportedModerate
Risedronate 5 mg/day vs placebo
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.74 [0.42, 1.3]Studies not reportedVery low
High‐dose vs low‐dose colchicine
Serious adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported